Skip to main content

Table 1 Breast cancer and prostate cancer repositioned drug candidates identified from analysis of LINCS. Complete lists of repositioned drug candidates for breast cancer and prostate cancer are shown in Additional file 13

From: A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer

 

Breast Cancer

 

Prostate Cancer

 

Total compounds

3678

 

4228

 

Compounds that are FDA drugs

632

 

676

 

Compounds that are FDA drugs for target disease

20

 

11

 

Compounds that are in clinical trial for target disease

154

 

106

 
 

UCDB

DCUB

UCDB

DCUB

Compounds with FDR < 0.05

2435

1875

2500

1668

Compounds that are clinical drugs with FDR < 0.05 (p-value)

131 (6.2E-8)

109 (2.7E-7)

82 (4.9E-5)

67 (4.8E-7)

FDA drugs with FDR < 0.05

427

325

456

317

FDA drugs with FDR < 0.05 in both UCDB and DCUB

244

 

291

 

FDA drugs for target disease with FDR < 0.05 (p-value)

20 (2.5E-4)

19 (2.7E-5)

10 (2.6E-2)

9 (5.3E-3)

AUC (p-value)

0.86 (<1.0E-6)

0.81 (<1.0E-6)

0.77 (9E-3)

0.83 (4.7E-5)

Number of MAG/DRG

237/700

75/100

333/100

46/100